Tag: Imetelstat

December 4, 2018

Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients

Geron (Nasdaq:GERN) today announced that results from IMbark, a Phase 2 clinical trial of imetelstat treatment in Intermediate-2 or High-risk...
September 27, 2018

Geron Cancels Janssen Collaboration, Share Price Drops

Geron and Johnson & Johnson’s subsidiary, Janssen Biotech, have terminated their partnership on development of a drug for two different...
September 27, 2018

Geron Announces Discontinuation of Imetelstat Collaboration by Janssen

Geron (Nasdaq:GERN) today announced that Janssen Biotech has terminated the 2014 Collaboration and License Agreement (CLA) with the Company. Janssen...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.
March 18, 2018

5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top

Second Sight, Juniper, Athersys, Aptose and ArQule were last week's five top-gaining NASDAQ biotech stocks. See what moved their share...
March 4, 2018

5 Top NASDAQ Biotech Stocks: Tenax on top with a 51.94 Percent Increase

This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to...